ABBV vs ELMD

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

ELMD exhibits exceptional financial health, anchored by a strong Piotroski F-Score of 8/9 and a debt-free balance sheet (Debt/Equity 0.00). While the Graham Number suggests a defensive value of $11.28, the stock's growth profile—highlighted by a very low PEG ratio of 0.35 and consistent earnings beats—justifies its current premium. With an intrinsic value of $30.39 and an analyst target of $37.00, the stock is well-positioned for further upside. The combination of high gross margins (78.23%) and strong ROE (20.20%) indicates a highly efficient business model.